Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819313 | 1.00 | CTSK (0.59) | CTSKEPHX2CASRCTSLCTSS | |
| SCHEMBL5637804 | 0.82 | CTSK (0.72) | CTSKCTSLCTSSCTSBCTSH | |
| SCHEMBL4813599 | 0.82 | CTSK (0.72) | CTSKCTSLCTSSCTSBCTSH | |
| SCHEMBL4813617 | 0.82 | CTSK (0.72) | CTSKCTSLCTSSCTSBCTSH | |
| SCHEMBL4813612 | 0.82 | CTSK (0.72) | CTSKCTSLCTSSCTSBCTSH | |
| SCHEMBL6488429 | 0.79 | CTSK (0.64) | CTSKCTSLCTSS | |
| SCHEMBL6488436 | 0.79 | CTSK (0.64) | CTSKCTSLCTSS | |
| SCHEMBL4817847 | 0.79 | EPHX2 (0.49) | CTSKEPHX2CASR | |
| SCHEMBL8356928 | 0.79 | CTSK (0.79) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL14260226 | 0.76 | CTSK (1.00) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | claimed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | claimed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | claimed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | claimed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | CTSK 1/4885EPHX2 2447/4885CASR 2818/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | CTSK 1/4885EPHX2 2408/4885CASR 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.